در هنگام جستجو کلمه در قسمت عنوان میتوانید کلمات مورد جستجو را با کاراکتر (-) جدا کنید.
کاربرد نوع شرط:
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Breast cancer,Biomarker,MicroRNA,miR-155
- چکیده:
- چکیده انگلیسی: Background: Breast cancer incidence rates have been continuously increasing in majority nations with significant higher portion of cancer-related mortality in low- and middle-income countries. Developing new biomarker is an emerging field in the breast cancer research. Application of a promising minimally invasive biomarker, circulating microRNA, for additional improvement of diagnosis, prognosis, and therapeutic monitoring in breast cancer is not well corroborated. Materials and Methods: To uncover the potential use of circulating miR-155 expression as a clinical biomarker in breast cancer, we analyzed 102 breast cancer patients at diagnosis and after treatment as well as 15 healthy women. Total RNA was isolated from patient’s plasma and expression of circulating miR-155 was measured with quantitative reverse transcription polymerase chain reaction (qRT-PCR). The expression levels of circulating miR-155 were compared according to the effect of treatment, clinicopathological variables, and progression-free survival. Results: In comparison to the healthy women, expression of circulating miR-155 levels were significantly higher (medians were 18.49±19 and 1.28±0.18, respectively; p<0.0001). The expression levels of miR-155 were significantly diminished after patients completed surgery and chemotherapy (medians were 18.49±19 at diagnosis and 1.32±0.22 after treatment, respectively; p<0.0001). Patients older than 40 years old expressed higher circulating miR-155 than those younger than 40 years-old (medians were 28.92±22 and 4.19±2.49, respectively; p<0.0001). Circulating miR-155 was significantly higher in patients with tumors larger than 5 cm (44.27±2.6 vs 9.17±6.9, p=0.03). MiR-155 expression levels were not significantly different according to various tumor grades, subtypes, and clinical stages. Although longer follow-up is required, progression-free survivals of patients with upregulation of circulating miR-155 were significantly longer (mean survivals were 77 and 65 weeks, Log-rank (Mantel-Cox) test p=0.038). Conclusion: Expression of circulating miR-155 expression was significantly elevated in breast cancer patients and was decreased after treatment. Therefore, circulating miR-155 is potentially applicable as diagnostic therapeutic monitoring marker in breast cancer.
- انتشار مقاله: 09-07-1398
- نویسندگان: Sumadi Lukman Anwar,Dewi Sahfitri Tanjung,Meutia Srikandi Fitria,Aprilia Indra Kartika,Dwi Nur Indah Sari,Dinna Rakhmina,Tirta Wardana,Indwiani Astuti,Sofia Mubarika Haryana,Teguh Aryandono
- مشاهده
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Apoptosis,p53,Cyclin D1,Metformin,HeLa cell
- چکیده:
- چکیده انگلیسی: Background: Cervical cancer is one of the most prevalent gynecological cancers worldwide and contributes in high
mortality of Indonesian women. The efficacy of chemotherapy as a standart therapy for cervical cancer decreases because
it frequenly rises adverse effects. Recent studies have found that metformin has a potential anticancer effect mostly
through reduction of cyclin expression and activation of Activated Adenosine Monophosphate Kinase (AMPK). This
study aimed to investigate the effect of metfomin on expression of cyclin D1 and p53 and apoptosis in HeLa cancer cell
line. Methods: HeLa cells were treated with various doses of metformin and doxorubicin as a positive control. Cytotoxic
effect of metformin was determined using the MTT assay. Immunocytochemistry was used to assess cyclin D1 and p53
expression and apoptosis levels of treated HeLa cells were analyzed using flowcytometry. Data of cyclin D1 expression
was statistically analyzed using the Kruskal-Wallis test followed by the Tamhane test, whilst ANOVA and Tukey post
Hoc tests were used to analyze data of p53 and apoptosis level. The significant value was p< 0.05. Results: Metformin
was able to inhibit proliferation of HeLa cells with IC50 60 mM. HeLa cells treated with 60 and 120 mM metformin
had lower cyclin D1 expression than HeLa cells treated without metformin and reached a significant difference (p=
0.001). Moreover, 30 mM or higher doses of metformin increase significantly p53 expression (p< 0.001). Induction of
apoptosis was observed in HeLa cells treated with all doses of metformin and reached statistically difference (p= 0.04
and p < 0.001). Conclusion: Metformin can modulate cyclin D1 and p53 expression in HeLa cancer cell line, leading
to inhibition of cell proliferation and induction of apoptosis. Other cyclin family members, CDK inhibitors and AMPK
signaling should be further investigated in order to know mechanism of metformin action.- انتشار مقاله: 01-03-1397
- نویسندگان: Ratih Dewi Yudhani,Indwiani Astuti,Mustofa Mustofa,Dono Indarto,Muthmainah Muthmainah
- مشاهده
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Breast cancer,Biomarker,MicroRNA,miR-21,circulating
- چکیده:
- چکیده انگلیسی: Background: Aberrant patterns of microRNA expression have been highlighted as a potential clinical biomarker in
breast cancer as the most frequent cancer among women that contributes nearly a quarter of total cancer incidence in
2018. Upregulation of microRNA-21 (miR-21) is associated with adverse clinical outcomes in breast cancer. However,
the use of circulating free miR-21 as a non-invasive biomarker for diagnosis and therapeutic monitoring in breast
cancer is not well established. We quantified the levels of circulating miR-21 expression and analyzed their correlation
with clinicopathological variables and progression-free survival. Materials and Methods: This initial study included
a cohort of 102 breast cancer patients of different subtypes and clinicat stages. We also included 15 unrelated healthy
women. Venous blood from patients was collected at diagnosis and after treatment of surgery and chemotherapy.
MiR-21 expression was quantified from total RNA fraction isolated from patient’s plasma. Quantitative reverse
transcription polymerase chain reaction (qRT-PCR) was used to analyzed miR-21 expression. Results: Expression of
circulating miR-21 was significantly elevated in breast cancer patients compared to healthy women (median miR-21
expression levels were 7.67±2.2 and 1.28±0.16, respectively; p<0.0001). Significant reduction of miR-21 expression was
observed in breast cancer patients after completion of surgery and chemotherapy (median miR-21 expression levels were
7.67±2.2 at diagnosis and 2.16±1.28 after treatment, respectively; p<0.0001). MiR-21 expression was higher in breast
cancer patients younger than 40-year-old but was not significantly different according to different histopathological
grades and clinical stages at diagnosis. Patients with upregulation of circulating miR-21 were associated with poor
progression-free survival (median survival 72 vs 86 weeks, respectively; log-rank (Mantel-Cox) test, p=0.049).
Conclusion: MiR-21 expression was upregulated in breast cancer patients and might serve as a therapeutic monitoring
marker.- انتشار مقاله: 06-09-1397
- نویسندگان: Sumadi Lukman Anwar,Dwi Nur Indah Sari,Aprilia Indra Kartika,Meutia Srikandi Fitria,Dewi Sahfitri Tanjung,Dinna Rakhmina,Tirta Wardana,Indwiani Astuti,Sofia Mubarika Haryana,Teguh Aryandono
- مشاهده